Key Highlights
- Diluted loss per share was USD 5.13; the estimate was a USD 6.60 loss.
- Net income of USD 17.84 million replaced a net loss of USD 10.12 million.
- Loss from operations was USD 4.37 million, against USD 5.72 million.
- Cash and cash equivalents stood at USD 3.10 million on September 30, 2026.
Adagio Medical Holdings (NASDAQ:ADGM) recorded Net Income of USD 17.84 million in the third quarter of 2026, where the third quarter of 2025 had brought a net loss of USD 10.12 million. Basic net income per share was USD 2.40. Diluted net loss per share was USD 5.13, against USD 19.73 a year earlier and an estimated loss of USD 6.60.
No Revenue was reported in either quarter. Per-share amounts are adjusted for the reverse split of November 6, 2026.
Operating Costs and What Moved Them
Research and development expense was USD 1.80 million, against USD 2.77 million, and selling, general and administrative expense was USD 2.57 million, against USD 2.92 million. The filing ties the lower selling, general and administrative figure mainly to lower professional services spending and regulatory reporting expenses, with higher Payroll and personnel costs working the other way. Combined, cost of revenue and operating spending came to USD 4.37 million, against USD 5.72 million, which equals the loss from operations.
The Convertible Notes Adjustment
A Fair Value adjustment on the convertible notes produced a gain of USD 22.95 million, against a loss of USD 3.51 million. Interest expense was USD 0.84 million, against USD 0.75 million, while interest income of USD 0.04 million, against USD 0.08 million. Other items netted to income of USD 22.21 million, where the prior-year quarter netted to expense of USD 4.40 million.
Over the nine months ended September 30, 2026, net income was USD 4.13 million, against a net loss of USD 21.78 million. The loss from operations was USD 14.51 million, against USD 17.92 million, and the diluted net loss per share was USD 17.13, against USD 42.48.
Balance Sheet and the Going Concern Language
Cash and cash equivalents were USD 3.10 million at September 30, 2026, against USD 17.11 million at December 31, 2025. Inventory, net, was USD 2.72 million, against USD 1.67 million, with total Assets of USD 29.86 million, against USD 43.25 million. Net convertible notes payable stood at USD 2.01 million, against USD 21.04 million, and total liabilities at USD 11.50 million, against USD 30.85 million. Total stockholders' Equity was USD 18.36 million, against USD 12.40 million.
Net cash used in Operating Activities was USD 14.0 million over the nine months. In the filing, the company says it does not expect existing cash and cash equivalents to cover operating and Capital Expenditure needs for 12 months after the financial statements were issued. Those factors, it states, cast substantial doubt on its ability to continue as a going concern.






Please wait processing your request...